FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 851 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Introducing our new podcast for researchers February 4, 2022 Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response July 15, 2022 The American Society of Clinical Oncology and the American Cancer Society:... February 1, 2022 NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous... June 8, 2021 Load more HOT NEWS Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... Research with integrity – all the fun of the FAIR Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That... FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC
